<DOC>
	<DOCNO>NCT00723827</DOCNO>
	<brief_summary>The purpose surveillance evaluate postmarketing safety efficacy Temodal capsule ( temozolomide ) actual condition use , understand follow point question doubt : - Incidence adverse event actual condition use ( Serious Nonserious Adverse Events ) ; - Adverse Drug Reactions show direction use ( state Unexpected Adverse Reaction ) ; - Adverse Event cause misuse , abuse , drug interaction ; - Other information concern safety efficacy .</brief_summary>
	<brief_title>Temodal ( Temozolomide ) Post Marketing Surveillance Protocol ( Study P05557AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Participants prescribe temozolomide local labeling : participant newly diagnose glioblastoma multiforme ; participant malignant glioma , glioblastoma multiforme anaplastic astrocytoma , show recurrence progression standard therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>